Date: June 29, 2021 Your Name: Jie Wei Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., ,provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | x |
| 3 | Royalties or licenses | None | x |
| 4 | Consulting fees | None | x |

| 5 | Payment or honoraria for lectures, presentations, | None | X |
|----|--|------|---|
| | speakers bureaus, manuscript writing or educational events | | |
| 6 | Payment for expert testimony | None | X |
| 7 | Support for attending meetings and/or travel | None | X |
| | | | |
| 8 | Patents planned, issued or pending | None | X |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | X |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other | None | x |
| 13 | services Other financial or non- financial interests | None | X |
| | | | |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Guan Ye Nai Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | x |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Yi Dai Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | x |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Xun Jun Huang Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | x |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Ming Yue Xiong Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | x |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Xiang You Yao Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| 1 | All support for the present manuscript (e.g., ,provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Time frame: Since the initial | x |
| | | T: | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: past None | x |
| 3 | Royalties or licenses | None | X |
| 4 | Consulting fees | None | x |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Zhi ning Huang Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | x |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Si Nian Li Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | x |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Wei Jie Zhou Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | X |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Yan Huang Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | X |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Dong hong Deng Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., ,provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | X |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | X |
| 3 | Royalties or licenses | None | X |
| 4 | Consulting fees | None | X |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: June 29, 2021 Your Name: Peng Cheng Manuscript Title: Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | X |
| | manuscript (e.g., ,provision | | |
| | of study materials, medical | | |
| | writing, article processing | | |
| | charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | x |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | x |
| | | | |
| | | | |
| 4 | Consulting fees | None | x |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or | None | x |
|----|--|------|---|
| 6 | educational events Payment for expert testimony | None | x |
| 7 | Support for attending meetings and/or travel | None | X |
| 8 | Patents planned, issued or pending | None | x |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | x |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | X |
| 11 | Stock or stock options | None | x |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | X |
| 13 | Other financial or non- financial interests | None | X |

The authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: